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Background: There is growing concern regarding the increased incidence of bladder cancer in diabetic patients using pioglitazone. 
This study aimed to investigate the association between bladder cancer and the use of pioglitazone in Korean diabetics.
Methods: This retrospective, matched case-control study included a case group (n=329) of diabetic patients with bladder can-
cer who presented at the Severance Hospital from November 2005 to June 2011. The control group consisted of patients without 
bladder cancer (1:2 ratio matching for sex and age, n=658) who were listed on the Severance Hospital diabetes registry. 
Results: The percentage of subjects who had ever used pioglitazone was significantly lower in the case group than in the control 
group (6.4% vs. 15.0%, P<0.001). Multivariate conditional logistic analysis revealed that independent factors affecting bladder 
cancer were smoking (odds ratio [OR], 11.64; 95% confidence interval [CI], 6.56 to 20.66; P<0.001), coexisting cancer (OR, 6.11; 
95% CI, 2.25 to 16.63; P<0.001), and hemoglobin levels (OR, 0.78; 95% CI, 0.69 to 0.88; P<0.001). The OR of the history of pio-
glitazone use was 2.09 and was not significantly different between the two groups (95% CI, 0.26 to 16.81; P=0.488). 
Conclusion: A relationship between pioglitazone use and incidence of bladder cancer was not observed in Korean diabetic pa-
tients. This suggests that the risk for bladder cancer in Korean diabetic subjects treated with pioglitazone might be different from 
that of Caucasian populations. Large-scale, well-designed and multi-center studies are needed to further evaluate this relationship.
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INTRODUCTION
 
The expression of peroxisome proliferator activator-receptors 
(PPAR)-γ in normal uroepithelilal cells or in bladder cancer 
cells may cause antiproliferative effects [1] or potential tumor-
igenicity [2]. In preclinical animal studies, transitional papillo-
ma and carcinoma originated from the urothelium in the uri-
nary bladder and renal pelvis of Sprague-Dawley Wistar and 
Fisher strain rats of both sexes treated with 5/6 PPAR dual ag-
onists (α/γ) and one γ agonist (pioglitazone). These findings 
prompted a similar epidemiologic study in humans [3], and 
recent human clinical trials have caused growing concern re-
garding pioglitazone use in subjects with type 2 diabetes [4-6]. 
An interim report from a longitudinal cohort study concluded 
that short-term use of pioglitazone was not significantly asso-
ciated with an increased incidence of bladder cancer, but that 
using pioglitazone longer than 2 years was weakly associated 
with increased risk of bladder cancer [6]. Another epidemio-
logical study conducted in France suggested that use of piogli-
tazone is associated with risk of bladder cancer [5], resulting 
in a ban of pioglitazone in France. Based on these findings, the 
Food and Drug Administration of the United States of Ameri-
ca has been closely tracking data from an ongoing, 10-year ep-
idemiological study.
 There are numerous ethnic and cultural differences between 
Korean populations and Caucasian populations, including dif-
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ferences in medical milieu. Therefore it is essential to evaluate 
the association between pioglitazone use and bladder cancer 
in Koreans. This study investigated the association between 
the pioglitazone use and incidence of bladder cancer in dia-
betic Koreans. 
METHODS
Subjects and methods
In this retrospective, case-control study, clinical and laborato-
ry data from Severance Hospital at the Yonsei University Col-
lege of Medicine were retrieved from electronic medical re-
cords. The study protocol was approved by the Ethics Com-
mittee of the Yonsei University College of Medicine. Patients 
were eligible for enrollment if the following criteria were met: 
1) older than 20 years of age; 2) presenting with type 2 diabetes 
from November 2005 to June 2011; 3) bladder cancer diagno-
sis confirmed by cytology. Among the diabetic patients with 
bladder cancer, those who were dependent on pioglitazone at 
the time of or before the detection of bladder cancer were in-
cluded. Patients who were 1) diagnosed with bladder cancer 
prior to the diagnosis of diabetes, 2) treated with pioglitazone 
after being diagnosed with bladder cancer, or 3) found to have 
benign pathology results were excluded. This study took into 
account different classes of anti-diabetic agents, potential con-
founding variables believed to be associated with the risk of 
bladder cancer (e.g., age, sex, duration of diabetes, obesity, al-
cohol, smoking, and anti-diabetic agents), and potential un-
derlining medical conditions (e.g., malignancy, renal insuffi-
ciency with HbA1c, hemoglobin, albumin, total cholesterol). 
Records and data were reviewed for validation by two endo-
crinologists.
 The population of subjects who were free of bladder cancer 
was supplemented with a case-control study from the Sever-
ance diabetes registry to avoid incomplete or missing data on 
potential confounders. For each diabetic subject with bladder 
cancer and a history of pioglitazone use, one control was ran-
domly selected by SAS version 9.2 (SAS Institute Inc., Cary, NC, 
USA) at the medical research supporting section of Yonsei 
University, after 1:2 ratio-matching for sex and age. Diabetic 
subjects on pioglitazone were classified into either the case 
group with bladder cancer or the control group without blad-
der cancer. Members of the case group and control group were 
further categorized into the following subgroups based on the 
type of anti-diabetic drug they were using: pioglitazone, other 
thiazolidinedione, metformin, sulfonylurea, insulin, α-
glucosidase inhibitors, dipeptidyl peptidase (DPP)-4 inhibitors, 
and no medication.
 Anthropometric and biochemical variables were measured. 
HbA1c was measured by high performance liquid chromatog-
raphy using Variant II Turbo (Bio-Rad Laboratories, Hercules, 
CA, USA). An abbreviated modification of diet in renal disease 
study equation was used to estimate glomerular filtration rate 
(GFR) as follows: estimated GFR (mL/min/1.73 m2)=186×
(creatinine/88.4)-1.154×(age)-0.203 ×(0.742, if female). 
Confounding variables
Confounding variables were determined based on habits at 
the time of first diagnosis of bladder cancer. Smoking habits 
were categorized into never smoked, current smoker, and ex-
smoker if they quit more than 1 year prior to the study. Smok-
ing frequency was calculated as packs per year (PPY), where 1 
PPY=20 cigarettes/day for 1 year. Alcohol consumption was 
defined as alcoholic intake greater than 20 g/day, as stated in 
the World Health Organization guidelines. The cumulative 
dose of pioglitazone was calculated by multiplying daily doses 
of pioglitazone (15 mg) by the number of days prescribed. The 
cumulative doses of pioglitazone in the case group was calcu-
lated based on the number of doses prescribed according to 
Severance Hospital medical records from the first day of the 
pioglitazone prescription to the day of bladder cancer diagno-
sis. 
Statistical analyses 
Statistical parameters were calculated using PASW Statistics 
version 18 (SPSS, Chicago, IL, USA) and P<0.05 was consid-
ered significant. Continuous variables with a normal distribu-
tion were expressed as mean±standard deviation and com-
pared using an independent t-test. Pearson’s chi-square test 
and Fisher’s exact tests were employed for comparison of cate-
gorical variables. A multivariate conditional logistic regression 
model was used to determine the factors associated with blad-
der cancer in diabetes patients, and the skewed data were sum-
marized using median values and an inter-quartile range.
RESULTS
Of the 53,569 subjects presenting with type 2 diabetes in Sev-
erance Hospital from November 2005 to June 2011, 507 sub-
jects were diagnosed with both bladder cancer and diabetes. 
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Of these 507 subjects, 178 were excluded, leaving 329 patients 
who fulfilled the aforementioned criteria for final inclusion in 
the study. Of the 53,569 eligible subjects regardless of bladder 
cancer, 6,069 subjects had never used pioglitazone. A total of 
658 age- and sex-matched diabetics without bladder cancer 
were enrolled as the control group. 
 Type 2 diabetic subjects with and without bladder cancer 
were classified into the case group and the control group, re-
spectively (Fig. 1). Baseline characteristics of the participants 
are shown in Table 1. Age (69.4±9.9 years) and male dominant 
gender ratio (5.32:1) were similar between the two groups after 
matching for sex and age. The duration of diabetes (9.66±16.0 
years vs. 8.66±8.7 years) and body mass index (24.0±3.1 kg/m2 
Table 1. Demographics and confounder variables
Variable Case group (n=329) Control group (n=658) P value 
Age, yr 69.4±9.9 69.4±9.9 
Male sex, n (%) 277 (84.2) 554 (84.2) 
DM duration, yr 9.66±16.0 8.66±.8.7 0.295
Height, cm 165.2±7.9 165.7±7.7 0.316
Weight, kg 65.7±10.5 65.9±10.5 0.779
BMI, kg/m2 24.0±3.1 25.1±12.0 0.116
Alcohol, n (%) 164 (51.9)  181 (27.6) <0.001 
Smoking history, n (%) 211 (64.1) 77 (11.7) <0.001 
PPY of smokers 26.8±34.1 26.4±17.2 0.899
Other cancer, % 11 2 <0.001 
History of use of pioglitazone, % 6.4 15 <0.001 
Pioglitazone use, day 555.4±606.6 770.6±772.8 0.216
363.5 (IQR,100.3-632.3) 485.00 (IQR, 230.0-1135.0) 0.254
Cumulative dose until cancer, mg 5,876.9±5,500.3 11,558.6±10,842.6 0.001
5,400.0 (IQR, 1,350.0-8,861.3) 7,275.0 (IQR, 3,450.0-17,025.0) 0.033
Creatinine, mg/dL 1.53±1.2 1.52±5.8 0.983
eGFR, mL/min/1.73 m2 61.40±26.3 83.6±285.5 0.161
HbA1c, % 7.22±1.2 7.41±4.9 0.688
Hemoglobin, g/dL 12.7±5.1 13.4±2.5 0.008
Total protein, g/dL 6.71±0.8 7.60±10.4 0.138
Albumin, g/dL 3.97±0.7 4.14±0.6 <0.001 
AST, IU/L 72.0±842.9 30.3±70.4 0.383
ALT, IU/L 35.3±251.3 25.3±28.9 0.343
Total cholesterol, mg/dL 158.8±41.1 157.4±41.9 0.645
Continuous variables are presented as mean±standard deviation or median (interquartile range). Also categorical variables are presented as 
number and percent (%).
DM, diabetes mellitus; BMI, body mass index; PPY, pack per years; IQR, interquartile range; eGFR, estimated glomerular filtration rate; HbA1c, 
hemoglobin A1c; AST, aspartate aminotransferase; ALT, alanine aminotransferase.
All type 2 diabetes 
subjects  
(n=53,569)
With bladder  
cancer group  
(n=329)
Pioglitazone (+) 
(n=21)
Pioglitazone (-) 
(n=308)
Pioglitazone (+) 
(n=99)
Pioglitazone (-) 
(n=559)
Age-sex 1:2 matched
without bladder cancer 
group (n=658)
Fig. 1. Study design: matched case-control. 
vs. 25.1±12.0 kg/m2) were not significantly different between 
the two groups. History of alcohol use (51.9% vs. 27.6%, P<
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0.001), smoking (64.1% vs. 11.7%, P<0.001), and proportions 
of other coexisting cancers (11.0% vs. 2.0%, P<0.001) were 
significantly higher in the case group than in the control group. 
However, smoking levels as assessed by PPY were not different 
between the two groups (26.8±34.1 vs. 26.4±17.2, P=0.899). 
The percentage of subjects who had ever used pioglitazone 
(6.4% vs. 15.0%, P<0.001), the number of pioglitazone prescrip-
tion days (555.4±606.6 days vs. 770.6±772.8 days, P=0.216; 
median 363.5 [interquartile range, 100.3 to 632.3] vs. median 
485.0 [interquartile range, 230.0 to 1,135.0], P=0.254), and the 
cumulative dose of pioglitazone (5,876.9±5,500.3 mg vs. 
11,558.6±10,842.6 mg, P=0.001; median 5,400.0 [interquar-
tile range, 1,350.0 to 8,861.3] vs. 7,275.0 [interquartile range, 
3,450.0 to 17,025.0], P=0.033) were significantly lower in the 
case group than in the control group. Hemoglobin (12.7±5.1 
g/dL vs. 13.4±2.5 g/dL, P=0.008) and albumin (3.97±0.7 mg/
dL vs. 4.14±0.6 mg/dL, P<0.001) were significantly lower in 
the case group than in the control group, but HbA1c (7.22± 
1.2% vs. 7.41±4.9%), total cholesterol, aspartate aminotrans-
ferase or alanine aminotransferase levels were not (Table 1).
 An analysis of anti-diabetic medications used in the case 
group revealed that sulfonylurea (46.4%) is the most widely 
used, followed by no medication (17.4%), insulin (12.6%), 
metformin only (8.5%), rosiglitazone (5.7%), and pioglitazone 
(6.4%). In the control group, most subjects did not take medi-
cation (26.6%), followed by sulfonylurea (20.5%), metformin 
only (14.0%), insulin (11.8%), and pioglitazone (15.0%). The 
proportion of patients undergoing combination therapy of 
metformin and pioglitazone was not significantly different be-
tween the two groups. The proportion of pioglitazone use was 
significantly different between the case group and the control 
group (6.4% vs. 15.0%, P<0.001) (Fig. 2).
 A multivariate conditional logistic regression analysis re-
vealed that independent factors affecting bladder cancer were 
smoking (odds ratio [OR], 11.6; 95% confidence interval [CI], 
6.56 to 20.66; P<0.001), coexisting cancer (OR, 6.11; 95% CI, 
2.25 to 16.63; P<0.001), and low level of hemoglobin (OR, 
0.78; 95% CI, 0.69 to 0.88; P<0.001) (Table 2). The OR of pio-
glitazone use was only 2.09 and was not significantly different 
between the two groups (95% CI, 0.26 to 16.81; P=0.488). 
Moreover, the OR of cumulative doses of pioglitazone was 1.00 
(95% CI, 1.00 to 1.00; P=0.041). Cumulative doses of piogli-
tazone were unrelated to bladder cancer in this study (Table 2). 
DISCUSSION
A growing number of epidemiologic evidence suggests that 
there is a significantly higher risk of several malignancies, such 
as pancreatic, esophageal, breast, and colon cancer in subjects 
with diabetes [7,8]. Clinical trials and several retrospective 
registry analyses indicate that diabetic subjects who have used 
pioglitazone may have an increased risk of bladder cancer 
[4,6,9-12]. Although pioglitazone insignificantly increased 
bladder cancer risk in the Taiwanese population [12], charac-
teristics associated with bladder cancer in Taiwanese subjects 
are different from those in Caucasian subjects. In Caucasian 
populations there was a weakly increased risk of bladder can-
cer after more than 2 years of pioglitazone therapy [6], where-
as bladder cancer in Taiwanese diabetics patients occurred 
within 2 years of the initiation of therapy and no patients with 
a cumulative dose >28,000 mg developed bladder cancer [12]. 
Based on these findings, Tseng [12] suggested that pioglitazone 
has an immediate effect on the risk of bladder cancer or late 
pioglitazone use in patients with a high risk of bladder cancer.
Table 2. Independent variables predicting bladder cancer  
Variable OR 95% CI for OR P value 
Alcohol 1.563 0.941-2.598 0.085
Smoking 11.643 6.563-20.655 <0.001 
History of pioglitazone use 2.09 0.260-16.814 0.488
Coexisting cancer 6.113 2.247-16.627 <0.001 
Hemoglobin 0.779 0.689-0.880 <0.001 
Albumin 0.968 0.645-1.453 0.876
OR, odds ratio; CI, confidence interval.Pio
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Fig. 2. Proportion of anti-diabetic medication use. SU, sulfo-
nylurea; DPP-4, dipeptidyl peptidase-4.
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 According to the Korean Central Cancer Registry (KCCR) 
[13], the age-standardized rate (ASR) of bladder cancer in Ko-
rea decreased between 2004 and 2008; the ASRs of bladder 
cancer across both genders for 2004, 2005, 2006, 2007, and 
2008 were 5.2, 5.2, 5.0, 5.0, and 4.9/100,000, respectively. In 
the male population, the ASRs for 2004 through 2008 were 
10.0, 10.0, 9.8, 9.5, and 9.2/100,000, respectively (Supplemen-
tary Fig. 1). Pioglitazone was first launched in 2003 in Korea. 
Its market share in the Korean oral hypoglycemic agent mar-
ket started relatively low (ranging from 3% to 5% in 2007) and 
increased slightly to 7% in 2008, when the patent on original 
pioglitazone expired and the generic drug launched. The rela-
tionship between market share, increased pioglitazone pre-
scriptions, and the ASR of bladder cancer in Korea seems to 
indicate there is not a direct correlation between bladder can-
cer and pioglitazone. This simple proof-of-concept data analy-
sis suggests that pioglitazone may not be associated with the 
occurrence of bladder cancer, and the present study tested this 
hypothesis.
 Considering the differences in ethnicity and medical milieu 
between the Korean population and the Caucasian population, 
and using simple proof-of-concept data analysis [14,15], the 
authors hypothesized that pioglitazone use might not be asso-
ciated with bladder cancer. The present study primarily fo-
cused on the characteristics of Korean type 2 diabetic patients 
with bladder cancer and on the statistical association between 
pioglitazone use and the occurrence of bladder cancer using a 
case-control study. This study used data from the Severance 
Hospital diabetes registry to avoiding incomplete or missing 
information about potential confounders. The study has three 
main findings. First, diabetic patients with bladder cancer in 
the Severance Hospital data pool were relatively old (69.4±9.9 
years) and predominantly male (5.32 ratio over female), which 
is similar to data from the Korea Central Cancer Registry. Sec-
ond, contrary to what was expected, the proportion of patients 
using pioglitazone, as well as the total cumulative dose of pio-
glitazone, was significantly higher in diabetics without bladder 
cancer. In a multivariate logistic analysis, the OR of pioglitazone 
use was 2.09 and was not significantly different between the 
two groups (95% CI, 0.26 to 16.81, P=0.488). Third, in accor-
dance with previous reports, independent variables associated 
with bladder cancer included coexisting malignancy, smoking, 
and anemia. It is well-known that smoking is the primary risk 
factor of bladder cancer, especially in males [16]. Recent re-
ports on the risk of bladder cancer among diabetic patients 
treated with pioglitazone in Caucasian and Asian populations 
[6,12] adopted Cox proportional hazards models for all calcu-
lations of the hazard ratio of bladder cancer and did not con-
sider smoking history or current smoking status. This study 
performed a multiple conditional regression analysis adjusting 
for smoking, a well-known risk factor of bladder cancer. In 
this study, pioglitazone use was not significantly different be-
tween the bladder cancer and cancer-free group; however, the 
OR of smoking was 11.6, confirming that smoking is an im-
portant risk factor of bladder cancer. Confirmation of smok-
ing status is essential in accurately assessing the incidence of 
bladder cancer. In addition, the fact that diabetic patients with 
bladder cancer were significantly more likely to have other 
cancers could be attributed to smoking. Establishing a cause-
effect relationship regarding anemia was unsuccessful due to 
the limitations of a cross-sectional study, but it is highly prob-
able that the anemia was an epiphenomenon, possibly due to 
bladder bleeding in cancer patients.
 Unlike results from previous studies, this study found the 
incidence of bladder cancer among diabetic patients to be un-
related to pioglitazone use. Possible explanations for this in-
clude differences in pioglitazone dosing, in addition to an ab-
solutely low incidence of bladder cancer. The typical dose of 
pioglitazone in South Korea is 15 mg, while the typical dose in 
Western nations is of 30 to 40 mg. Indeed, in the case group 
and control group, all subjects had taken 15 mg of pioglitazone 
daily, with the exception of a single subject who had taken 7.5 
mg of pioglitazone daily. In addition, the age-adjusted bladder 
cancer incidence in the U.S. was 37.7/100,000 in 2007 [17], 
and the age-standardized rate in South Korea was 9.2/100,000 
in 2008 [13]. Only 165 patients with bladder cancer were in-
cluded in the previously mentioned Taiwanese study, among 
54,928 patients who were analyzed. This study, however, in-
cluded 329 cases of bladder cancer even though the data came 
from only one study center. 
 This case-control study had several limitations. First, there 
were incomplete or missing data for several variables known 
to be associated with bladder cancer, such as history of expo-
sure to chemical toxins and presence of comorbid conditions 
such as urinary disease. Also, the cumulative dose of piogli-
tazone was calculated as the amount of drug prescribed since 
the first prescription made at the tertiary hospital until the day 
of diagnosis of bladder cancer. These calculations were based 
on a review of medical records, which caused difficulties in 
calculating pioglitazone intake prior to visiting the tertiary 
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center. As a result, the actual cumulative dose of pioglitazone 
may have been underestimated. In addition, a survival analysis 
comparing the incidence of bladder cancer between diabetic 
patients with and without the history of pioglitazone use was 
not included in this study. Therefore, this cross-sectional study 
might be confounded by the duration of observation for each 
group. Lastly, because this study was a retrospective analysis, 
there may be a recall bias.
 Data from 3,500 bladder cancer patients across several uni-
versity hospitals, which manage over 35% of all bladder cancer 
patients in South Korea, are currently being analyzed in an at-
tempt to overcome the limitations of the current study. In ad-
dition, a request has been made to the National Health Insur-
ance Database to provide data for all pioglitazone prescriptions 
written to diabetic patients with or without bladder cancer, af-
ter which a hazard ratio will be calculated using the Cox re-
gression model. This ongoing study aims to investigate the 
time to diagnosis of bladder cancer, cumulative dose of piogli-
tazone, presence of other cancers, and smoking and alcohol 
history in the patient registry by enrolling approximately 
200,000 patients who have been diagnosed with diabetes and 
are receiving care across several representative hospitals. Thus, 
in the future this ongoing study will conduct a more accurate 
assessment of the association between the pioglitazone use and 
incidence of bladder cancer among diabetic patients.
 In summary, this study did not observe a significantly in-
creased risk of bladder cancer among patients treated with pi-
oglitazone in Korean diabetics. However, the study also is un-
able to absolutely exclude the possibility of a relationship be-
tween pioglitazone and bladder cancer because the OR for pi-
oglitazone use was relatively high (2.09, P=0.484). This suggests 
that the risk of bladder cancer in Korean diabetics treated with 
pioglitazone might be different from that of Caucasian popu-
lation.
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Supplementary Fig. 1. Frequency of bladder cancer and pioglitazone market in Korea. (A) Both. (B) Male. (C) Female. The crude 
rate (CR), a rate based on the frequency of cancer in the entire population, is calculated as follow: CR (per 100,000 person-years)= 
(Number of events/Corresponding person-years of observation)×100,000. The an age-standardized rate (ASR) is a weighted av-
erage of crude age-specific rates, where the CRs are calculated for different age groups and the weights are the proportions of 
persons in the corresponding age groups of a standard population. 
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